Vitamin A and Thyroid Hormones Key to Developing Sharp Vision, New Study Reveals
A groundbreaking study published today in Proceedings of the National Academy of Sciences details how a delicate interplay between a vitamin A derivative and thyroid hormones during fetal development is crucial for the formation of sharp vision in humans. The findings from Johns Hopkins University researchers could reshape our understanding of eye growth and pave the way for novel treatments for debilitating vision disorders like macular degeneration and glaucoma.
The research centers on the foveola, the central region of the retina responsible for our most detailed vision. Understanding how this critical area develops is paramount, especially as it’s the first part of the eye to deteriorate in individuals with macular degeneration. “This is a key step toward understanding the inner workings of the center of the retina,” explained a senior researcher involved in the study. “By better understanding this region and developing organoids that mimic its function, we hope to one day grow and transplant these tissues to restore vision.”
Pioneering Research with Lab-Grown Retinas
For years, scientists have struggled to fully grasp the intricacies of human eye development, largely because commonly used animal models – mice, fish, and others – don’t replicate the unique cellular structure of the human retina. To overcome this hurdle, the Johns Hopkins team pioneered a new approach utilizing organoids: small, three-dimensional tissue clusters grown from fetal cells.
By meticulously monitoring these lab-grown retinas over several months, researchers were able to pinpoint the cellular mechanisms that sculpt the foveola. Their focus was on cone cells, the light-sensitive cells responsible for color vision and visual acuity. These cells come in three varieties – blue, green, and red – each sensitive to different wavelengths of light.
The Unique Human Visual System
Humans possess a unique visual system, boasting all three types of cone cells, allowing us to perceive a broader spectrum of colors than most other animals. The foveola, despite comprising only a small portion of the retina, accounts for approximately 50% of our visual perception. Notably, the foveola contains a high concentration of red and green cones, while blue cones are largely absent and distributed more broadly across the rest of the retina. This specific arrangement has long been a puzzle for scientists.
A Shift in Understanding Cone Cell Development
The study reveals that the distribution of cones within the foveola isn’t simply a matter of blue cones migrating elsewhere, as previously theorized. Instead, the research demonstrates a dynamic process of cell fate conversion during early development. Initially, a limited number of blue cones are present in the foveola between weeks 10 and 12 of gestation. However, by week 14, these blue cones undergo a transformation, converting into red and green cones.
This conversion is driven by two key processes. First, a molecule derived from vitamin A, known as retinoic acid, is broken down, limiting the production of new blue cones. Second, thyroid hormones actively encourage existing blue cones to transition into red and green cones. “First, retinoic acid helps set the pattern. Then, thyroid hormone plays a role in converting the leftover cells. That’s very important because if you have those blue cones in there, you don’t see as well,” a lead researcher explained.
Implications for Future Therapies
These findings challenge the long-held belief that cone cells maintain their identity throughout development. “The main model in the field from about 30 years ago was that these cells decide what they’re going to be, and they remain this type of cell forever,” one researcher noted. “Our data supports a different model. These cells actually convert over time, which is really surprising.”
The Johns Hopkins team is now focused on refining their organoid models to more accurately replicate human retina function. This work holds immense promise for developing innovative therapies for vision loss, including cell replacement therapy – the potential to grow healthy photoreceptors and transplant them to restore lost vision. “The goal with using this organoid tech is to eventually make an almost made-to-order population of photoreceptors,” said Katarzyna Hussey, a former doctoral student and current molecular and cell biologist at CiRC Biosciences in Chicago. “These are very long-term experiments, and of course we’d need to do optimizations for safety and efficacy studies prior to moving into the clinic. But it’s a viable journey.”
This research represents a significant leap forward in our understanding of vision development and offers a beacon of hope for those suffering from currently incurable eye diseases.
Source:Hussey, K. A., et al. (2026). A cell fate specification and transition mechanism for human foveolar cone subtype patterning. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2510799123. https://www.pnas.org/doi/10.1073/pnas.2510799123
